Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marqibo with UK ALL R3 for Relapsed ALL
NCT02879643Phase 1Completed
- Sponsor
- Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium
- Start
- Jan 2017
- Primary completion
- Jul 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of vincristine in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (3 arms), sponsored by Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium. Primary endpoint: Dose Limiting Toxicities at 9 weeks. Started Jan 2017; status: completed.
02
Drugs
vincristine
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02879643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879643.